Get in on Repligen Corp.’s (RGEN) buy-in window today!

With 0.56 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.59 million shares. During the session, the Medical Instruments & Supplies company that operates in wider Healthcare sector, reached to the highest price of $208.07 whereas the lowest price it dropped to was $200.33. The 52-week range on RGEN shows that it touched its highest point at $204.00 and its lowest point at $110.45 during that stretch. It currently has a 1-year price target of $187.23. Beta for the stock currently stands at 1.04.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RGEN was up-trending over the past week, with a rise of 5.85%, but this was up by 17.82% over a month. Three-month performance surged to 35.14% while six-month performance rose 18.02%. The stock gained 5.23% in the past year, while it has gained 13.45% so far this year. A look at the trailing 12-month EPS for RGEN yields 2.03 with Next year EPS estimates of 1.77. For the next quarter, that number is 0.33. This implies an EPS growth rate of -47.28% for this year and 2.50% for next year. EPS is expected to decline by -6.23% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 35.07%.

Float and Shares Shorts:

At present, 55.56 million RGEN shares are outstanding with a float of 51.91 million shares on hand for trading. On Jan 11, 2024, short shares totaled 5.82 million, which was 10.43% higher than short shares on Dec 14, 2023. In addition to Mr. Anthony J. Hunt as the firm’s CEO & Director, Mr. James R. Bylund serves as its Chief Operating Officer.

Institutional Ownership:

Through their ownership of 103.95% of RGEN’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RGEN since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With RGEN analysts setting a high price target of $211.00 and a low target of $148.00, the average target price over the next 12 months is $187.23. Based on these targets, RGEN could surge 3.44% to reach the target high and fall by -27.45% to reach the target low. Reaching the average price target will result in a decline of -8.22% from current levels.

Summary of Insider Activity:

Insiders traded RGEN stock several times over the past three months with 0 Buys and 2 Sells. In these transactions, 0 shares were bought while 4,788 shares were sold. The number of buy transactions has increased to 22 while that of sell transactions has risen to 21 over the past year. The total number of shares bought during that period was 81,669 while 28,346 shares were sold.